Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study

SIMPLE SUMMARY: For a few years, lenalidomide plus dexamethasone (Len/Dex) has become a new standard of care for newly diagnosed multiple myeloma (NDMM) patients who are not eligible for autologous stem cell transplantation. The FIRST trial showed that continuous therapy with Len/Dex is superior in...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Fabro, Vittorio, Di Giorgio, Mary Ann, Leotta, Valerio, Duminuco, Andrea, Bellofiore, Claudia, Markovic, Uros, Romano, Alessandra, Bulla, Anna, Curto Pelle, Angelo, Elia, Federica, Di Raimondo, Francesco, Conticello, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452433/
https://www.ncbi.nlm.nih.gov/pubmed/37627065
http://dx.doi.org/10.3390/cancers15164036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452433/
https://www.ncbi.nlm.nih.gov/pubmed/37627065
http://dx.doi.org/10.3390/cancers15164036

Ejemplares similares